/ /

  • linkedin
  • Increase Font
  • Sharebar

    Quiz: 2017 ACC/AHA/HFSA Update to 2013 HF Guidelines

     

    The correct answer is: D. Neither A or B 

    According to 2017 ACC/AHA/HFSA updated HF management guidelines, concomitant administration of an ACE-I and ARNI (or administering an ARNI <36 hours after stopping an ACE-I) is not recommended, based on the risk for for angioedema. Likewise, a patient with a history of angioedema should not receive an ARNI due to this risk. In patients with HFrEF NYHA class II or III who remain symptomatic despite tolerating an ACE-I or an ARB, ACC/AHA/HFSA recommends replacement with an ARNI. New clinical trial data suggests that replacing an ACE-I or ARB with an ARNI may decrease hospitalizations and mortality in such patients.    

     

    References

    1. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017 Aug 8;136(6):e137-e161. doi: 10.1161/CIR.0000000000000509.

    2. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–16.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available